Detalles de la búsqueda
1.
Lecanemab in Early Alzheimer's Disease.
N Engl J Med
; 388(1): 9-21, 2023 01 05.
Artículo
Inglés
| MEDLINE | ID: mdl-36449413
2.
Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease.
Ann Neurol
; 95(2): 288-298, 2024 Feb.
Artículo
Inglés
| MEDLINE | ID: mdl-37830926
3.
Alzheimer's Targeted Treatments: Focus on Amyloid and Inflammation.
J Neurosci
; 43(47): 7894-7898, 2023 11 22.
Artículo
Inglés
| MEDLINE | ID: mdl-37968119
4.
Predicting clinical progression trajectories of early Alzheimer's disease patients.
Alzheimers Dement
; 20(3): 1725-1738, 2024 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-38087949
5.
Plasma Aß42/Aß40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease.
Alzheimers Dement
; 20(2): 1214-1224, 2024 Feb.
Artículo
Inglés
| MEDLINE | ID: mdl-37932961
6.
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial.
Alzheimers Dement
; 2024 Apr 17.
Artículo
Inglés
| MEDLINE | ID: mdl-38629508
7.
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry-based test with algorithm combining %p-tau217 and Aß42/40 ratio to identify presence of brain amyloid.
Alzheimers Dement
; 2024 Mar 16.
Artículo
Inglés
| MEDLINE | ID: mdl-38491912
8.
Lewy body dementia: Overcoming barriers and identifying solutions.
Alzheimers Dement
; 20(3): 2298-2308, 2024 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-38265159
9.
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.
Alzheimers Dement
; 19(4): 1227-1233, 2023 04.
Artículo
Inglés
| MEDLINE | ID: mdl-35971310
10.
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials.
Alzheimers Dement
; 19(2): 696-707, 2023 02.
Artículo
Inglés
| MEDLINE | ID: mdl-35946590
11.
Increasing the Cognitive Screening Efficiency of Global Phase III Trials in Early Alzheimer Disease: The Cognitive Task Force.
Alzheimer Dis Assoc Disord
; 36(3): 185-191, 2022.
Artículo
Inglés
| MEDLINE | ID: mdl-35622461
12.
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.
Alzheimers Dement
; 16(1): 131-143, 2020 01.
Artículo
Inglés
| MEDLINE | ID: mdl-31668596
13.
Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.
Pharmacoepidemiol Drug Saf
; 25(4): 413-21, 2016 Apr.
Artículo
Inglés
| MEDLINE | ID: mdl-26889887
14.
Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Alzheimers Res Ther
; 16(1): 105, 2024 May 10.
Artículo
Inglés
| MEDLINE | ID: mdl-38730496
15.
Sudden unexpected death in epilepsy in lamotrigine randomized-controlled trials.
Epilepsia
; 54(1): 135-40, 2013 Jan.
Artículo
Inglés
| MEDLINE | ID: mdl-23030403
16.
Understanding Barriers Along the Patient Journey in Alzheimer's Disease Using Social Media Data.
Neurol Ther
; 12(3): 899-918, 2023 Jun.
Artículo
Inglés
| MEDLINE | ID: mdl-37060417
17.
Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial.
JAMA Netw Open
; 6(4): e237230, 2023 04 03.
Artículo
Inglés
| MEDLINE | ID: mdl-37040116
18.
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.
Alzheimers Dement (N Y)
; 9(1): e12377, 2023.
Artículo
Inglés
| MEDLINE | ID: mdl-36949897
19.
Risk of cancer in patients exposed to gabapentin in two electronic medical record systems.
Pharmacoepidemiol Drug Saf
; 21(2): 214-25, 2012 Feb.
Artículo
Inglés
| MEDLINE | ID: mdl-22144034
20.
Background incidence of liver chemistry abnormalities in pediatric clinical trials for conditions with and without underlying liver disease.
Regul Toxicol Pharmacol
; 62(2): 329-35, 2012 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-22057095